Hormone therapy has endured a rather bumpy history after the Women’s Health Initiative published clinical trial data in 2002 ...

The FDA is reevaluating longtime warnings on hormone replacement therapy products for menopausal women. Some advocates for ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

Experts worry the warning on vaginal estrogen menopause treatments is doing more harm than good and is not supported by science.

Sarepta Therapeutics shares surged 34% in after-hours trading on Wednesday after the company said it would slash 500 jobs, or ...

( NewsNation) — The head of the U.S. Food and Drug Administration signaled Thursday that he supports changing or removing the ...

Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on ...

New data shows no increased cardiovascular risk of the osteoporosis drug vs anabolic agents — and even suggests a lower risk.

Dr. Marty Makary, the agency’s commissioner, said too many women avoid hormone therapy because the risks have been overstated ...

Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Following the death of two teenage patients with Duchenne muscular dystrophy following Elevidys treatment, Sarepta ...